[Clinical study of ethinyl estradiol sulfonate in conservative therapy of prostate cancer].
Ethinylestradiol sulfonate is an orally applicable, potent depot estrogen with steroid structure. With a dosage of 2 mg per week it shows a distinct antigonadotropic and antiandrogenic effect. Its suitability for the hormone therapy of the carcinoma of the prostate is clinically and cytologically confirmed. It seldom has undesirable side effects. The oral application necessary only once a week guarantees a continuous supply of active substances with a good compliance by the patients.
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004343:Drug Implants; D004997:Ethinyl Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood
D000726:Androgen Antagonists; D004343:Drug Implants; D012738:Sex Hormone-Binding Globulin; C025723:ethinyl estradiol sulfonate; D013739:Testosterone; D004997:Ethinyl Estradiol; D007986:Luteinizing Hormone
Die klinische Prüfung von Ethinylestradiolsulfonat zur konservativen Therapie des Prostatakarzinoms.